Medication info

Empagliflozin/Metformin Hydrochloride Tablets 12.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
JW Pharmaceutical Co., Ltd.
Appearance
A biconvex, oval film-coated tablet with a dark brownish purple color.
Packaging
60 tablets/box [10 tablets/PTP x 6], 10 tablets/box [10 tablets/PTP x 1], 60 tablets/bottle
Approval status
Active

MFDS item code 202302606 · Approved 2023.09.01

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's previous dose of metformin. If the patient tolerates empagliflozin 10 mg (total daily dose) well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive the same doses of empagliflozin and metformin as before. When this medicine is co-administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as remembered. However, do not take a double dose at one time; if this occurs, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the initial dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Patients in Whom the Medicine Must Not Be Used, item 2)). Elderly patients In patients 75 years of age or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
JW Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood glucose dysregulation
  • cardiovascular diseases
View approved original text

This medication contains empagliflozin and metformin, effectively assisting in blood glucose control for adult patients with type 2 diabetes, along with dietary regulation and exercise therapy. It is especially used when blood glucose is not sufficiently controlled, and patients with cardiovascular diseases should refer to precautions regarding the occurrence of cardiovascular events under professional guidance. Overall, this medication is used to improve blood glucose management and cardiovascular health.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's previous dose of metformin. If the patient tolerates empagliflozin 10 mg (total daily dose) well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive the same doses of empagliflozin and metformin as before. When this medicine is co-administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as remembered. However, do not take a double dose at one time; if this occurs, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the initial dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Patients in Whom the Medicine Must Not Be Used, item 2)). Elderly patients In patients 75 years of age or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication can cause a rare but serious side effect known as severe lactic acidosis, so regular checks on kidney function should be conducted to prevent this. Caution is needed as this medication may cause hypoglycemia when taken with other antidiabetic medications like insulin or sulfonylureas. Patients with moderate to severe renal impairment, acute kidney issues, severe infections, or heart failure should not take this medication. Patients undergoing examinations using iodine contrast agents should stop this medication 48 hours prior to the examination and resume only after confirming normal kidney function. It is safest for pregnant or breastfeeding women not to take this medication, and women who may become pregnant should also avoid it. This medication may cause side effects such as increased urination, urinary tract infections, and genital infections; if any abnormal symptoms appear, consult a doctor immediately. Especially elderly patients or those at risk of dehydration should be cautious as hypotension or dizziness may occur due to fluid loss. Regular blood tests to monitor kidney function and vitamin B12 levels during medication is essential. No special effects have been reported during driving or operating machinery, but caution is advised for symptoms of hypoglycemia or dizziness. In case of overdose, visit a hospital immediately for appropriate treatment, as rapid medical intervention is necessary due to the risk of lactic acidosis.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • ketoacidosis
  • lactic acidosis
  • decreased vitamin B12 absorption
  • decreased fluid volume
  • nausea
  • vomiting
Show 173 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • dysgeusia
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • perineal necrosis
  • pyelonephritis
  • urosepsis
  • hypotension
  • dehydration
  • low blood pressure
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • ischemic colitis
  • gastrointestinal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • salpingo-oophoritis
  • vestibular neuritis
  • headache
  • sensory loss
  • position-related dizziness
  • dizziness
  • drowsiness
  • weakness
  • chest discomfort
  • chest pain
  • fever
  • facial swelling
  • chills
  • strange sensation
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight gain
  • abnormal electrocardiogram
  • decreased hemoglobin
  • increased hemoglobin
  • positive Helicobacter test
  • positive urine red blood cells
  • ureteral calculi
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • cervicitis
  • hyperglycemia
  • diabetes mellitus
  • hyponatremia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • visual disturbance
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • retinal detachment with a hole
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • phlegm retention
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open eye injury
  • pelvic fracture
  • road traffic accident
  • spleen injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • gallstones
  • hepatitis
  • otalgia
  • position-related vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • vulvar pruritus
  • genital pruritus
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

A biconvex, oval film-coated tablet with a dark brownish purple color.

Package unit

60 tablets/box [10 tablets/PTP x 6], 10 tablets/box [10 tablets/PTP x 1], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.